260 related articles for article (PubMed ID: 23648072)
1. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.
Grossi F; Genova C; Gaitan ND; Dal Bello MG; Rijavec E; Barletta G; Sini C; Donato C; Beltramini S; Pronzato P; Porcile G; Boccardo F; Walzer S
Lung Cancer; 2013 Aug; 81(2):236-40. PubMed ID: 23648072
[TBL] [Abstract][Full Text] [Related]
2. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan.
Shen LJ; Chou H; Huang CF; Chou GM; Chan WK; Wu FL
Contemp Clin Trials; 2011 Jul; 32(4):485-91. PubMed ID: 21530679
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials and drug cost savings for Italian health service.
D'Ambrosio F; De Feo G; Botti G; Capasso A; Pignata S; Maiolino P; Triassi M; Nardone A; Perrone F; Piezzo M; Grimaldi AM; Palazzo I; De Stasio I; D'Aniello R; Morabito A; Pascarella G
BMC Health Serv Res; 2020 Nov; 20(1):1089. PubMed ID: 33243262
[TBL] [Abstract][Full Text] [Related]
4. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
5. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
6. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
[TBL] [Abstract][Full Text] [Related]
9. The costs of conducting clinical research.
Emanuel EJ; Schnipper LE; Kamin DY; Levinson J; Lichter AS
J Clin Oncol; 2003 Nov; 21(22):4145-50. PubMed ID: 14559889
[TBL] [Abstract][Full Text] [Related]
10. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
11. The impact of new cancer drugs in real practice oncology: a monoinstitutional experience.
Jirillo A; Imbevaro S; Mazurek M
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):702-5. PubMed ID: 22239469
[TBL] [Abstract][Full Text] [Related]
12. Incremental drug treatment cost in HIV-positive patients in industry-sponsored clinical trials.
Perrín RS; López FJ
Ann Pharmacother; 2008 Nov; 42(11):1586-91. PubMed ID: 18780807
[TBL] [Abstract][Full Text] [Related]
13. Drug cost avoidance resulting from cancer clinical trials.
Bredin C; Eliasziw M; Syme R
Contemp Clin Trials; 2010 Nov; 31(6):524-9. PubMed ID: 20840876
[TBL] [Abstract][Full Text] [Related]
14. [Access to cancer care: the cost of treatment matters].
Tirelli U
Recenti Prog Med; 2014 May; 105(5):181-3. PubMed ID: 24873939
[TBL] [Abstract][Full Text] [Related]
15. Drug cost savings in phase III hematological oncology clinical trials in a university hospital.
Herledan C; Ranchon F; Schwiertz V; Baudouin A; Karlin L; Ghesquières H; Salles G; Rioufol C
Hematol Oncol; 2020 Oct; 38(4):576-583. PubMed ID: 32469095
[TBL] [Abstract][Full Text] [Related]
16. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
17. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
Gadgeel SM; Ivy P; Chen W; Mauer J; Smith D; Lorusso P
Clin Lung Cancer; 2011 Jul; 12(4):218-23. PubMed ID: 21726820
[TBL] [Abstract][Full Text] [Related]
18. [Cost of medications in the oncology sector in the context of health economics].
Walter E; Batista A
Wien Med Wochenschr; 2008; 158(7-8):227-33. PubMed ID: 18500477
[TBL] [Abstract][Full Text] [Related]
19. The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.
Tran DT; Akpinar I; Fedorak R; Jonsson E; Mackey J; Richer L; Jacobs P
J Pharm Pharm Sci; 2017; 20(1):407-414. PubMed ID: 29197429
[TBL] [Abstract][Full Text] [Related]
20. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
